|
| 37722697 | Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment. | Annu Rev Pathol | 2024 |
| 37849038 | Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer. | Cancer Discov | 2024 |
| 37748191 | MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling. | Mol Cancer Ther | 2024 |
| 37838086 | Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation. | J Thorac Oncol | 2024 |
| 37678511 | HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies. | J Thorac Oncol | 2024 |
| 37870438 | Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors. | Mol Cancer Res | 2024 |
| 36346688 | Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group. | Clin Cancer Res | 2023 |
| 37487667 | Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study. | J Immunother Cancer | 2023 |
| 37589215 | Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. | Oncologist | 2023 |
| 37898613 | Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. | Nat Commun | 2023 |
| 37743366 | Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. | Nat Cancer | 2023 |
| 37652400 | DNA Methylation Signature of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. | Mod Pathol | 2023 |
| 37831210 | CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas. | Acta Neuropathol | 2023 |
| 37607324 | Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma. | J Clin Oncol | 2023 |
| 37814012 | Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. | Nat Cancer | 2023 |
| 36990277 | Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response. | Mod Pathol | 2023 |
| 37384866 | Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>KRAS G12C</i>-Mutant Non-Small Cell Lung Cancer. | JCO Precis Oncol | 2023 |
| 37247843 | Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC. | J Thorac Oncol | 2023 |
| 37182602 | Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification. | J Thorac Oncol | 2023 |
| 37399073 | Recurrent TRAK1::RAF1 Fusions in pediatric low-grade gliomas. | Brain Pathol | 2023 |
| 37097610 | Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer. | Clin Cancer Res | 2023 |
| 37432985 | Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. | Clin Cancer Res | 2023 |
| 36996377 | Clinical Targeted Next-Generation Panel Sequencing Reveals <i>MYC</i> Amplification Is a Poor Prognostic Factor in Osteosarcoma. | JCO Precis Oncol | 2023 |
| 36926116 | Distinct IDH1/2-associated Methylation Profile and Enrichment of <i>TP53</i> and <i>TERT</i> Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma. | Cancer Res Commun | 2023 |
| 36656937 | Germline study points to sarcoma pathways. | Science | 2023 |
| 36788094 | Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma. | Mod Pathol | 2023 |
| 36788080 | Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis. | Mod Pathol | 2023 |
| 36775193 | Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC. | J Thorac Oncol | 2023 |
| 36735656 | Mutant-RB1 circulating tumor DNA in the blood of unilateral retinoblastoma patients: What happens during enucleation surgery: A pilot study. | PLoS One | 2023 |
| 36798379 | Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. | bioRxiv | 2023 |
| 36729110 | Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas. | Clin Cancer Res | 2023 |
| 36494075 | Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers. | J Thorac Oncol | 2023 |
| 36862133 | Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach. | Clin Cancer Res | 2023 |
| 36240971 | Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228. | J Thorac Oncol | 2023 |
| 36325885 | A novel case of cutaneous myxoid spindle cell neoplasm with FMR1-ALK gene fusion and CD34/S100 co-expression. | J Cutan Pathol | 2023 |
| 32730814 | Precision medicine in non-small cell lung cancer: Current applications and future directions. | Semin Cancer Biol | 2022 |
| 35443736 | Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor. | Oncogenesis | 2022 |
| 35383193 | Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. | Nat Commun | 2022 |
| 35585047 | Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. | Nat Commun | 2022 |
| 35477182 | Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 35705560 | Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. | Nat Commun | 2022 |
| 35705558 | Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. | Nat Commun | 2022 |
| 35439652 | Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool. | Pathol Res Pract | 2022 |
| 35797508 | Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. | JCO Precis Oncol | 2022 |
| 35792876 | Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. | Clin Cancer Res | 2022 |
| 35760287 | POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. | J Thorac Oncol | 2022 |
| 35430374 | Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations. | J Mol Diagn | 2022 |
| 35365770 | Genomic landscape of endometrial carcinomas of no specific molecular profile. | Mod Pathol | 2022 |
| 35483883 | Corrigendum: Functional impact and targetability of <i>PI3KCA</i>, <i>GNAS</i>, and <i>PTEN</i> mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. | Cold Spring Harb Mol Case Stud | 2022 |
| 36506091 | Desmoplastic small round cell tumor cancer stem cell-like cells resist chemotherapy but remain dependent on the EWSR1-WT1 oncoprotein. | Front Cell Dev Biol | 2022 |